4DMT to Participate in Upcoming Investor Meetings

Core Insights - 4D Molecular Therapeutics is a late-stage biotechnology company focused on developing durable and disease-targeted therapeutics that aim to transform treatment paradigms and provide significant benefits to patients [2][3] Company Overview - The lead product candidate, 4D-150, is designed to treat blinding retinal vascular diseases by offering multi-year sustained delivery of anti-VEGF biologics through a single intravitreal injection, significantly reducing the treatment burden compared to current methods [2] - 4D-150 is currently in Phase 3 development for wet age-related macular degeneration and is also being studied for diabetic macular edema [2] - The second product candidate, 4D-710, is the first genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients via aerosol delivery [2] Upcoming Events - Management will present and hold one-on-one meetings at investor conferences in March 2026, including the Leerink Partners Mountain Meeting from March 22-25 and the RBC Capital Markets Global Ophthalmology Conference on March 24 at 3:45 p.m. GMT [1]